Baricitinib for Prurigo Nodularis: A Pilot Study on Efficacy and Safety

Table 1

Baseline patient demographics and disease characteristics (N = 12).

Age, mean ± SD, years	53.08 ± 12.35
Female, n (%)	7 (58.30%)
Body mass index, mean ± SD	26.70 ± 5.69
Duration since PN diagnosis, mean ± SD, years	5.75 ± 4.00
Number of nodules, mean ± SD	84.12 ± 28.59
Baseline NRS pruritus score	8.67 ± 1.37
Background of atopy, n (%)
(i) Allergic rhinitis	1 (8.33%)
(ii) Asthma	0 (0%)
(iii) Atopic dermatitis	0 (0%)
Previous systemic treatments, n (%)
(i) Prednisolone	6 (50%)
(ii) Methotrexate	2 (16.67%)
(iii) Azathioprine	2 (16.67%)
(iv) Dapsone	2 (16.67%)
(v) Phototherapy	0 (0%)